Quarterly Report · 10-Q

Wave Life Sciences, Inc.

WVENASDAQEQUITYCurrent

Quarterly Report

Filed Jul 30, 2026Accepted Jul 30, 2026, 3:50 AM EDTCIK 1631574Accession 0001193125-26-324949

Company context

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s lead pipeline programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Current securities

WVENASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

WAVE LIFE SCIENCES LTD. · 10-Q · Filed 2026-07-30

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

$0 Par Value Ordinary Shares

Symbol: WVE
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_8975296e-dca4-4695-8dc3-f997b1ca33ba

Dimensions: Not supplied

Accession 000119312526324949 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.